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Abstract The purpose of the study was to compare
breast-conserving therapy (BCT) and mastectomy (M) in
BRCA1/2 mutation carriers. Women with invasive breast
cancer and a pathogenic mutation in BRCA1 or BRCA2
were included in the study (n = 162). Patients treated with
BCT (n = 45) were compared with patients treated with M
(n = 118). Endpoints were local recurrence as first recur-
rence (LR), overall survival (OS), breast cancer death, and
distant recurrence. Cumulative incidence was calculated in
the presence of competing risks. For calculation of hazard
ratios and for multivariable analysis, cause-specific Cox
proportional hazards regression was used. Compared to M,
BCT was associated with an increased risk of LR in uni-
variable analysis (HR 4.0; 95 % CI 1.6–9.8) and in mul-
tivariable analysis adjusting for tumor stage, age, and use
of adjuvant chemotherapy (HR 2.9; CI 1.1–7.8). Following
M, all local recurrences were seen in the first 5 years after
breast cancer diagnosis. Following BCT, the rate of LR
continued to be high also after the first 5 years. The
cumulative incidence of LR in the BCT group was 15, 25,
and 32 % after 5, 10, and 15 years, respectively. There
were no significant differences between BCT and M for
OS, breast cancer death, or distant recurrence. BRCA1/2
mutation carriers treated with BCT have a high risk of LR,
many of which are new primary breast cancers. This must
be thoroughly discussed with the patient and is an example
of how rapid treatment-focused genetic testing could
influence choice of treatment.
Keywords Hereditary breast cancer  BRCA1/2  Breast-
conserving therapy  Radiotherapy  Mastectomy  Local
recurrence
Introduction
The knowledge on how BRCA1/2 mutation carriers should
be counseled and treated has evolved continuously over the
last two decades [1, 2]. Some important issues remain to be
solved, though. One of these is if breast-conserving therapy
(BCT) followed by postoperative radiotherapy is as good of
an alternative to mastectomy (M) for carriers as it is for
other breast cancer patients [3, 4]. Once a carrier has had a
breast cancer, the risk of contralateral breast cancer (CBC)
is indeed very high [5, 6]. It is reasonable to assume that
the risk of new primary breast cancers in the ipsilateral
breast is also high if breast tissue is still there for tumor
development. On the other hand, radiotherapy and other
adjuvant treatments change the microenvironment in the
breast and reduce the number of cancer precursors, and
M. P. Nilsson (&)  H. Olsson  N. Loman
Department of Oncology, Ska˚ne University Hospital, Clinical
Sciences, Lund University, Lund, Sweden
e-mail: martin.nilsson@med.lu.se
L. Hartman
Regional Cancer Centre South, Clinical Sciences, Lund
University, Lund, Sweden
U. Kristoffersson  E. Lanke
Department of Clinical Genetics, Laboratory Medicine Region
Ska˚ne and Lund University, Lund, Sweden
O. T. Johannsson
Department of Oncology, Landspitali University Hospital,
Reykjavik, Iceland
A˚. Borg
Department of Oncology and Pathology, Clinical Sciences, Lund
University, Lund, Sweden
K. Henriksson
Regional Cancer Centre South, Lund, Sweden
123
Breast Cancer Res Treat (2014) 147:571–578
DOI 10.1007/s10549-014-3115-3
could thereby, in addition to reducing the risk of true
recurrences, possibly also reduce the number of new pri-
mary tumors in the treated breast. It is not always possible
to differentiate an ipsilateral event being a true recurrence
or a new primary breast cancer. In the following, both are
denominated ‘‘local recurrences.’’
Results from cohort studies and case–control studies
have been conflicting regarding the risk of local recurrence
as first recurrence (LR) in carriers following BCT [7–17].
Importantly, no study to date has shown a survival differ-
ence between mutation carriers and noncarriers treated
with BCT or between carriers treated with BCT and car-
riers treated with M. However, BCT can be associated with
other disadvantages, such as the requirement of close fol-
low-up for a long time, most likely a recommendation of
adjuvant chemotherapy in case of a LR, and an increased
cancer-specific distress. Even though generally well toler-
ated, also M and bilateral mastectomy (BM) can for some
patients be associated with disadvantages, like a negative
impact on sexuality and body image [18]. The absolute
long-term risk of LR and survival endpoints are of pivotal
importance for mutation carriers with newly diagnosed
breast cancer to know, in order to be able to make informed
decisions about type of surgery.
To further evaluate the appropriateness of BCT in car-
riers, we conducted a cohort study. The aim of the study
was to compare LR and survival between carriers treated
with BCT and carriers treated with M.
Materials and methods
Study population
In an institutional database, where all persons that have
undergone mutation analysis of the BRCA1 and BRCA2
genes at a single institution in Lund, Sweden, are regis-
tered, all women with an invasive breast cancer stage I-III
diagnosed between 1975 and 2011 and a pathogenic
germline mutation in BRCA1 or BRCA2 were selected.
Women with variants of uncertain significance in BRCA1
or BRCA2 were not included. Out of 204 identified
patients, 183 had consented to longitudinal follow-up (or,
in case they were dead, their next of kin had consented), the
others were excluded.
Clinical data were abstracted from medical records and
pathology reports and supplemented by information from
self-reported questionnaires. TNM stage was classified
according to American Joint Committee on Cancer 7th
edition.
Patients with a diagnosis of ovarian cancer, except for
patients with no ovarian cancer recurrences and C10 years
elapsed after ovarian cancer diagnosis before breast cancer,
were excluded (n = 2). Another 8 patients were excluded
as we were not able to retrieve medical records. Of the
remaining 173 patients, 11 were treated with partial mas-
tectomy without postoperative radiotherapy; they were
excluded. For the present study, 162 patients thus consti-
tuted the study population. Only 9 of these patients had the
mutation analysis initiated after their death (on archived
tissue); for the others it was initiated while they were alive.
Due to a small number or patients, BRCA1 (n = 114) and
BRCA2 (n = 48) mutation carriers were grouped together
for analyses. Vital status was controlled in the Swedish
Census Register. Current analyses were based on follow-up
information through January 31, 2012.
Study endpoints
Study endpoints were local recurrence as first recurrence
(LR), overall survival (OS), breast cancer death, and distant
recurrence, for the pre-specified subgroups of patients
treated with BCT and M, respectively. If the final surgery
was M within 1 year after breast cancer diagnosis, the
patient was allocated to M, even if the first surgical pro-
cedure was a partial mastectomy. For the analysis of LR,
patients were censored at the date of last follow-up,
whereas distant or regional spread of cancer (breast cancer,
ovarian cancer, or another type of cancer) and death where
treated as competing risks. In other words, local recur-
rences occurring after a regional or a distant recurrence
were not considered. Further, patients treated with BCT
were censored at the time of prophylactic mastectomy. All
cases of LR were invasive. For women with bilateral breast
cancer, we were not able to distinguish death or distant
recurrence due to the first primary breast cancer from death
or distant recurrence due to the second primary breast
cancer.
Statistical analyses
Differences in patient, tumor, and treatment characteristics
between the BCT group and the M group were tested using
Fisher’s exact test. Cumulative incidence curves were
calculated for LR in the presence of other recurrences or
death as competing risks, and for breast cancer death and
distant recurrence in the presence of death of other cause
than breast cancer as competing risk. Kaplan–Meier curves
were used to illustrate OS. To compare event rates between
the treatment groups, cause-specific log-rank tests and Cox
regression analyses were used.
The following covariates were selected for multivariable
analyses: type of surgery, age at diagnosis, TNM stage, and
use of (neo)adjuvant chemotherapy. Age at diagnosis was
split at the median to account for nonlinear associations
and to make interpretations of the results easier. All tests
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and confidence intervals were two-tailed. All analyses
were conducted using the R statistical package (R 3.1.0),
using libraries survival and cmprsk. For the discussion
part, p values below 0.05 were considered statistically
significant.
Results
Study population
Forty-five patients were treated with BCT and 117 patients
had M as final surgery within one year from the breast
cancer diagnosis. Patient, tumor, and treatment character-
istics are listed and compared between these two groups in
Table 1. BCT was common in the time period 1990–1999,
M was more common before and after that. Tumors treated
with M were more often stage III and less often stage I than
tumors treated with BCT. Mean age at diagnosis was
43.3 years in both groups. Patients treated with M more
often received (neo)adjuvant chemotherapy (59 vs. 42 %)
and adjuvant endocrine therapy (37 vs. 13 %) than patients
treated with BCT. M was followed by postoperative
radiotherapy in 53 % of the cases. A bilateral prophylactic
mastectomy was done by 40 % of the patients in the BCT
group, and a contralateral prophylactic mastectomy was
done by 44 % of the patients in the M group. In both
groups, 67 % underwent a bilateral oophorectomy
(Table 1). Out of these 108 oophorectomies, 10 were done
prior to breast cancer diagnosis, 39 within two years fol-
lowing breast cancer diagnosis, and 59 at a later date. The
mean follow-up for OS was 12.9 years for patients alive at
the end of follow-up; 14.9 years in the BCT group and
12.1 years in the M group.
Table 1 Patient, tumor, and treatment characteristics
Variable BCT
(n = 45)
M
(n = 117)
pa
Mean follow-upb, years 14.9 12.1
Mean age at diagnosis, years 43.3 43.3
Median age at diagnosis, years 43.0 42.0
Year of diagnosis 0.019
1975–1989 8 (18 %) 31 (26 %)
1990–1999 24 (53 %) 34 (29 %)
2000–2011 13 (29 %) 52 (44 %)
TNM stage 0.023
I 22 (51 %) 33 (29 %)
II 17 (40 %) 53 (47 %)
III 4 (9 %) 26 (23 %)
Missing 2 5
Tumor grade 0.55
I 0 (0 %) 2 (3 %)
II 5 (33 %) 12 (19 %)
III 10 (67 %) 48 (77 %)
Missing 30 55
ER status 0.19
Negative 25 (78 %) 59 (63 %)
Positive 7 (22 %) 34 (37 %)
Missing 13 24
PgR status 1
Negative 23 (74 %) 67 (74 %)
Positive 8 (26 %) 24 (26 %)
Missing 14 26
(Neo)adjuvant chemotherapy 0.054
No 26 (58 %) 47 (41 %)
Yes 19 (42 %) 69 (59 %)
CMF-like 7 (16 %) 22 (19 %)
Anthracycline-based 11 (24 %) 29 (25 %)
Taxane-containing 0 16 (14 %)
Unknown 1 (2 %) 2 (2 %)
Adjuvant endocrine therapy 0.004
No 39 (87 %) 73 (63 %)
Yes 6 (13 %) 43 (37 %)
Postoperative radiotherapy
No 0 (0 %) 55 (47 %)
Yes 45 (100 %) 61 (53 %)
Oophorectomy
No 15 (33 %) 38 (32 %)
Yes 30 (67 %) 78 (67 %)
Bilateral prophylactic
oophorectomy
22 (49 %) 58 (50 %)
Ovarian cancer 8 (18 %) 18 (15 %)c
Palliative oophorectomy 0 2 (2 %)
Missing 0 1 (1 %)
Table 1 continued
Variable BCT
(n = 45)
M
(n = 117)
pa
Prophylactic mastectomyd 17 (40 %) 51 (44 %)
Contralateral breast cancer 12 of 43e 26 of 117
BCT breast-conserving therapy, M mastectomy, TNM tumor node
metastasis, ER estrogen receptor, PgR progesterone receptor,
(Neo)adjuvant = neoadjuvant or adjuvant
a Fisher’s exact test for all
b Mean follow-up for OS for patients alive at end of follow-up
c Another 3 patients in the M group and none in BCT group were
diagnosed with primary peritoneal carcinosis after a prophylactic
oophorectomy
d Bilateral prophylactic mastectomy after BCT and contralateral
prophylactic mastectomy after M
e Information on contralateral breast cancer missing for 2 patients in
the BCT group
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Local recurrence
The mean time at risk for LR was 6.0 years in the BCT
group and 8.8 years in the M group. The analysis of LR in
the BCT group was based on 11 cases of LR diagnosed at a
mean time of 7.6 years after breast cancer diagnosis; out of
11 cases of LR, 9 were isolated and 2 were concurrent with
a regional recurrence. In the M group, 9 cases of LR were
diagnosed at a mean time of 1.9 years after breast cancer
diagnosis; out of 9 cases of LR, 6 were isolated, 1 was
concurrent with a regional recurrence, and 2 were con-
current with a distant recurrence.
Compared to M, BCT was associated with an increased
risk of LR in univariable analysis (HR 4.0; 95 % CI
1.6–9.8) and in multivariable analysis adjusting for tumor
stage, age, and use of (neo)adjuvant chemotherapy (HR
2.9; CI 1.1–7.8) (Table 2). In this multivariable model,
younger age was associated with a higher risk of LR (\43
vs. C43 years: HR 2.7; CI 1.0–7.6), and use of
(neo)adjuvant chemotherapy resulted in a point estimate
below 1 but a wide confidence interval (HR 0.6; CI
0.2–1.7). Following M, all local recurrences were seen in
the first 5 years. As opposed to this, following BCT the rate
of LR continued to be high also after the first 5 years. The
cumulative risk of LR in the BCT group was 15, 25, and
32 % after 5, 10, and 15 years, respectively. The cumula-
tive risk of LR in the M group was 9 %, after 5, 10 as well
as 15 years (Table 3 and Fig. 1).
Overall survival, breast cancer death, and distant
recurrence
In univariable analysis, no difference in OS, breast cancer
death, or distant recurrence was seen between the BCT
group and the M group (Table 3 and Figs. 2, 3 4). In
multivariable analysis, adjusting for tumor stage, age at
diagnosis, and use of (neo)adjuvant chemotherapy, the
hazard ratios were higher, but remained inconclusive
Table 2 Univariable and
multivariable analysis for LR
LR local recurrence as first
recurrence, HR hazard ratio, CI
confidence interval,
M mastectomy, BCT breast-
conserving therapy, TNM tumor
node metastasis,
(Neo)adjuvant = neoadjuvant
or adjuvant
a Cox proportional hazards
model including all covariates.
n = 155, Events = 19
Univariable cox Multivariable coxa
n Events HR 95 % CI P HR 95 % CI P
160 20
Type of surgery 0.003 0.03
M 116 9 1.0 1.0
BCT 44 11 4.0 1.6–9.8 2.9 1.1–7.8
Age at diagnosis 0.06 0.06
C43 years 73 5 1.0 1.0
\43 years 87 15 2.6 1.0–7.1 2.7 1.0–7.6
TNM stage 0.10 0.52
I 55 11 1.0 1.0
II 70 6 0.35 0.1–1.0 0.6 0.2–1.7
III 30 2 0.42 0.1–1.9 1.1 0.2–5.8
(Neo)adjuvant chemotherapy 0.08 0.31
No 73 14 1.0 1.0
Yes 86 6 0.42 0.2–1.1 0.6 0.2–1.7
Table 3 Five-, ten-, and fifteen-year cumulative incidences (%) of death of any cause, breast cancer death, distant recurrence, and LR split on
surgical subgroups, and the corresponding hazard ratios
Death of any cause = 1-OS Breast cancer death Distant recurrence LR
M BCT M BCT M BCT M BCT
5-year (%) 17 20 14 20 25 25 9 15
10-year (%) 32 32 29 27 31 35 9 25
15-year (%) 37 42 29 34 31 35 9 32
Unadjusted HR (95 % CI) 1.0 1.0 (0.6–1.7) 1.0 1.1 (0.6–2.1) 1.0 1.2 (0.7–2.2) 1.0 4.0 (1.6–9.8)
Adjusted HRa (95 % CI) 1.0 1.4 (0.8–2.5) 1.0 1.6 (0.8–3.3) 1.0 1.8 (0.9–3.5) 1.0 2.9 (1.1–7.8)
OS overall survival, LR local recurrence as first recurrence, HR hazard ratio, CI confidence interval, M mastectomy, BCT breast-conserving
therapy
a Adjusted for TNM stage, age at diagnosis, and use of (neo)adjuvant chemotherapy
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(Table 3). The 5-, 10-, and 15-year cumulative incidences
are listed in Table 3.
Discussion
In this cohort study, we report that the risk of LR was
substantially higher after BCT than after M for BRCA1/2
mutation carriers. The cumulative incidence of LR
15 years after BCT was 32 %, which was significantly
higher than after M and is more than two-fold higher than
after BCT in the general population, where most tumors are
sporadic and the patients on average are older [19, 20].
Apart from type of surgery, younger age was also associ-
ated with an increased risk of LR. This can probably be
explained by the fact that carriers who get breast cancer
when they are very young are likely to have other predis-
posing or modifying factors of genetic or environmental
nature, and thus an increased risk of new primary breast
cancers [10, 15, 21].
Most of the case–control and cohort studies that have
been conducted to compare the outcome of BCT between
carriers and sporadic cases have reported point estimates of
LR that have been higher for carriers, although the dif-
ference in the majority of the studies have not obtained a
significant difference at p values \0.05, and it is therefore
difficult to draw firm conclusions from them. The largest
such study was reported by Pierce et al. in 2006 [12].
BRCA1/2 mutation carriers were matched with sporadic
cases, all treated with BCT. The 15-year risk of LR was
24 % for carriers and 17 % for sporadic cases (p = 0.19).
When patients that had done an oophorectomy were
excluded from the analysis, carriers had an increased risk
of LR (HR 1.9; p = 0.03). The same collaborative group
Fig. 2 Overall survival by type of surgery
Fig. 3 Cumulative incidence for breast cancer death by type of
surgery
Fig. 4 Cumulative incidence for distant recurrence by type of
surgery
Fig. 1 Cumulative incidence for local recurrence as first recurrence
by type of surgery
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published a different type of study in 2010, which is very
similar to ours in study design and is the only previous
study that has compared BCT and M for BRCA1/2 muta-
tion carriers [13]. No difference in survival was seen
between BCT and M, but patients treated with BCT had a
higher risk of LR: the 15-year risk of LR was 23.5 versus
5.5 %. Interestingly, chemotherapy decreased the risk, so
in the subgroup of BCT patients treated with chemother-
apy, the risk of LR was only 11.9 % after 15 years; a level
of risk comparable to what it is for sporadic cases and very
relevant for counseling and treatment of carriers today,
since a majority of them will receive chemotherapy if
diagnosed with a breast cancer. With the limitations of a
smaller number of patients and, therefore, no analyses of
modifying factors conducted separately in the BCT sub-
group, we also found a trend for a decreased risk of LR
after use of chemotherapy.
Metcalfe et al. [11] reported data from a large cohort of
carriers treated with partial mastectomy without any group
for comparison and found the 15-year risk of LR to be
15.8 %. Use of chemotherapy, oophorectomy, and post-
operative radiotherapy decreased the risk.
The age at diagnosis and uptake of oophorectomy was
similar, but the proportion of patients that received che-
motherapy was lower in our cohort than in the above-
mentioned studies, which could partly explain the higher
absolute risk of LR after BCT seen in our study. A study
that reported a higher risk of LR after BCT than what we
do, is a retrospective cohort study by Haffty et al., in which
the cumulative risk of LR 12 years after BCT was 49 %.
Of note, no mutation carriers in that cohort were treated
with adjuvant endocrine therapy or oophorectomy, and the
mean age at diagnosis was only 34 years [9].
In a recent meta-analysis by Valachis et al., no signifi-
cant difference in LR after BCT was seen between BRCA1/
2 mutation carriers and controls; however, a significant
difference was observed when the analysis was restricted to
studies with a median follow-up of C7 years [17].
A hypothesis that has been corroborated in a number of
studies is that early LRs are true recurrences and that late
LRs are in fact new primary breast cancers; the latter group
probably accounts for the majority of LR [9, 13]. We point
out that our cohort consists of mutation carriers ascertained
through a cancer genetic center, and a majority of them
belong to multiple-case families. Under a model where the
risk of late LR is modified by genetic and environmental
factors, this risk of LR is higher for these carriers than for
carriers ascertained through population-based programs.
The decreased risk of LR conferred by adjuvant therapy
could be mediated not only through killing of breast cancer
cells from the primary tumor, but also through an effect on
breast cancer precursors and changes in the microenvi-
ronment of the breast, making new tumor formation less
likely. The difference in the risk of LR between carriers
and sporadic cases is less clear in studies where more
adjuvant treatment has been used and a majority of the
patients have done an oophorectomy, supporting the notion
that these measures reduce the risk for new primary breast
cancers in the ipsilateral, as well as the contralateral,
breast.
In our study, the survival comparisons between BCT and
M should be interpreted with caution. M was more com-
mon than BCT in the time period 1975–1989. Patients who
died before they were known mutation carriers could be
included in the study, but patients that were still alive when
BRCA1/2 testing was introduced in the mid-90s were
probably more likely to be included, resulting in survi-
vorship bias. M was also more common in the time period
2000–2011, when adjuvant treatment was more common
and modern than before.
Neither our cohort nor any of the other cohorts in pub-
lished studies is large enough to properly adjust for all
possible biases and confounders. Furthermore, in obser-
vational studies of surgical decisions, bias can never be
fully accounted for.
In the general population, large randomized trials of
breast cancer patients have not shown a difference in sur-
vival between BCT and M. Still, in the general population,
patients that are diagnosed with a LR have an inferior
survival compared to patients without a LR [22]. Despite
the fact that some studies of BRCA1/2 mutation carriers
have shown a very high risk of LR, no study to date has
shown a difference in survival. This contradiction could
possibly be explained by a larger proportion of new pri-
mary breast cancers among carriers, which are less
aggressive than early true recurrences, and more often
curable [13]. However, given large enough sample sizes
and a cohort with a high rate of LR following BCT, a
difference in long-term survival between BCT and M
would be expected for carriers, since not all new primary
breast cancers are curable.
Apart from the inability to make reliable survival
comparisons, there are other limitations to our study. First,
the follow-up is too short to estimate cumulative lifetime
risks of LR, which has not been done in previous studies
either. Second, a small number of patients result in point
estimates with wide confidence intervals and the inability
to include some potentially important variables in the
multivariable models. Still, our study confirms some of the
findings from the larger collaborative study by Pierce et al.
Third, by including breast cancer patients from 1975 and
onwards, the proportion of patients receiving adjuvant
treatment is lower than what it is today, which can over-
estimate the risk of LR after BCT. Fourth, we were not able
to separate true local recurrences from new primary breast
cancers by means of pathology or localization in the breast.
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The number of mutation carriers opting for M and BM
has increased over the last decade, and the number opting
for BCT has decreased [23]; the trend is expected to con-
tinue further with evidence of a survival benefit with BM
now starting to emerge [5, 24, 25]. In the future, studies on
the risk of LR after BCT in mutation carriers will therefore
be harder to carry out and randomized trials are very
unlikely. Still, there is a need for more studies, since BCT
is considered an acceptable option for mutation carriers
today. Data from retrospective studies can give relatively
unbiased estimates of LR, but cannot properly measure
psychosocial endpoints. In future studies, for an optimal
generalizability to current standards, a very high proportion
of patients treated with chemotherapy and prophylactic
oophorectomy is needful. Furthermore, a long-term follow-
up is demanded for estimation of cumulative lifetime risks
of LR, which are pivotal for carriers with newly diagnosed
breast cancer to know in order to make informed decisions
about type of surgery.
In conclusion, BRCA1/2 mutation carriers treated with
BCT and who resemble our cohort regarding ascertain-
ment, age at diagnosis, adjuvant treatment, uptake of
oophorectomy etc., have a high risk of LR, many of which
are probably new primary breast cancers. This must be
thoroughly discussed with the patient and is an example of
how rapid treatment-focused genetic testing could influ-
ence choice of treatment.
Acknowledgments The study was approved by the Regional Ethi-
cal Review Board in Lund, and complies with the current laws of
Sweden. The research was funded by grants from Ska˚ne County
Counsil’s Research and Development Foundation, The Swedish
Breast Cancer Association (BRO), The Swedish Cancer Society, and
BioCARE.
Conflict of interest The authors declare that they have no conflict
of interest.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and the source are credited.
References
1. Tung N (2011) Management of women with BRCA mutations: a
41-year-old woman with a BRCA mutation and a recent history
of breast cancer. JAMA, J Am Med Assoc 305(21):2211–2220.
doi:10.1001/jama.2011.678
2. Lynch HT, Snyder C, Casey MJ (2013) Hereditary ovarian and
breast cancer: what have we learned? Annals of oncology
24(Suppl 8):viii83–viii95. doi:10.1093/annonc/mdt313
3. Bordeleau L, Panchal S, Goodwin P (2010) Prognosis of BRCA-
associated breast cancer: a summary of evidence. Breast Cancer
Res Treat 119(1):13–24. doi:10.1007/s10549-009-0566-z
4. Croshaw RL, Marshall ML, Williams TL, Erb KM, Julian TB
(2011) Prophylactic and Therapeutic Breast Conservation in
BRCA1/2 mutation carriers. Int J Breast cancer 2011:481563.
doi:10.4061/2011/481563
5. Evans DG, Ingham SL, Baildam A, Ross GL, Lalloo F, Buchan I,
Howell A (2013) Contralateral mastectomy improves survival in
women with BRCA1/2-associated breast cancer. Breast Cancer
Res Treat 140(1):135–142. doi:10.1007/s10549-013-2583-1
6. Rhiem K, Engel C, Graeser M, Zachariae S, Kast K, Kiechle M,
Ditsch N, Janni W, Mundhenke C, Golatta M, Varga D, Preisler-
Adams S, Heinrich T, Bick U, Gadzicki D, Briest S, Meindl A,
Schmutzler RK (2012) The risk of contralateral breast cancer in
patients from BRCA1/2 negative high risk families as compared
to patients from BRCA1 or BRCA2 positive families: a retro-
spective cohort study. BCR: Breast Cancer Res 14(6):R156.
doi:10.1186/bcr3369
7. Brekelmans CT, Tilanus-Linthorst MM, Seynaeve C, vd Ouwe-
land A, Menke-Pluymers MB, Bartels CC, Kriege M, van Geel
AN, Burger CW, Eggermont AM, Meijers-Heijboer H, Klijn JG
(2007) Tumour characteristics, survival and prognostic factors of
hereditary breast cancer from BRCA2-, BRCA1- and non-
BRCA1/2 families as compared to sporadic breast cancer cases.
Eur J Cancer 43(5):867–876. doi:10.1016/j.ejca.2006.12.009
Oxford, England: 1990
8. Garcia-Etienne CA, Barile M, Gentilini OD, Botteri E, Rotmensz
N, Sagona A, Farante G, Galimberti V, Luini A, Veronesi P,
Bonanni B (2009) Breast-conserving surgery in BRCA1/2
mutation carriers: are we approaching an answer? Ann Surg
Oncol 16(12):3380–3387. doi:10.1245/s10434-009-0638-7
9. Haffty BG, Harrold E, Khan AJ, Pathare P, Smith TE, Turner BC,
Glazer PM, Ward B, Carter D, Matloff E, Bale AE, Alvarez-
Franco M (2002) Outcome of conservatively managed early-
onset breast cancer by BRCA1/2 status. Lancet 359(9316):
1471–1477. doi:10.1016/s0140-6736(02)08434-9
10. Kirova YM, Savignoni A, Sigal-Zafrani B, de La Rochefordiere
A, Salmon RJ, This P, Asselain B, Stoppa-Lyonnet D, Fourquet A
(2010) Is the breast-conserving treatment with radiotherapy
appropriate in BRCA1/2 mutation carriers? Long-term results and
review of the literature. Breast Cancer Res Treat 120(1):119–126.
doi:10.1007/s10549-009-0685-6
11. Metcalfe K, Lynch HT, Ghadirian P, Tung N, Kim-Sing C, Ol-
opade OI, Domchek S, Eisen A, Foulkes WD, Rosen B, Vesprini
D, Sun P, Narod SA (2011) Risk of ipsilateral breast cancer in
BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat
127(1):287–296. doi:10.1007/s10549-010-1336-7
12. Pierce LJ, Levin AM, Rebbeck TR, Ben-David MA, Friedman E,
Solin LJ, Harris EE, Gaffney DK, Haffty BG, Dawson LA, Narod
SA, Olivotto IA, Eisen A, Whelan TJ, Olopade OI, Isaacs C,
Merajver SD, Wong JS, Garber JE, Weber BL (2006) Ten-year
multi-institutional results of breast-conserving surgery and
radiotherapy in BRCA1/2-associated stage I/II breast cancer.
J Clin Oncol 24(16):2437–2443. doi:10.1200/jco.2005.02.7888
13. Pierce LJ, Phillips KA, Griffith KA, Buys S, Gaffney DK, Moran
MS, Haffty BG, Ben-David M, Kaufman B, Garber JE, Merajver
SD, Balmana J, Meirovitz A, Domchek SM (2010) Local therapy
in BRCA1 and BRCA2 mutation carriers with operable breast
cancer: comparison of breast conservation and mastectomy.
Breast Cancer Res Treat 121(2):389–398. doi:10.1007/s10549-
010-0894-z
14. Robson ME, Chappuis PO, Satagopan J, Wong N, Boyd J, Goffin
JR, Hudis C, Roberge D, Norton L, Begin LR, Offit K, Foulkes
WD (2004) A combined analysis of outcome following breast
cancer: differences in survival based on BRCA1/BRCA2 muta-
tion status and administration of adjuvant treatment. BCR: Breast
Cancer Res 6(1):R8–R17. doi:10.1186/bcr658
15. Robson M, Levin D, Federici M, Satagopan J, Bogolminy F,
Heerdt A, Borgen P, McCormick B, Hudis C, Norton L, Boyd J,
Offit K (1999) Breast conservation therapy for invasive breast
Breast Cancer Res Treat (2014) 147:571–578 577
123
cancer in Ashkenazi women with BRCA gene founder mutations.
J Natl Cancer Inst 91(24):2112–2117
16. Seynaeve C, Verhoog LC, van de Bosch LM, van Geel AN,
Menke-Pluymers M, Meijers-Heijboer EJ, van den Ouweland
AM, Wagner A, Creutzberg CL, Niermeijer MF, Klijn JG, Bre-
kelmans CT (2004) Ipsilateral breast tumour recurrence in
hereditary breast cancer following breast-conserving therapy. Eur
J Cancer 40(8):1150–1158. doi:10.1016/j.ejca.2004.01.017
Oxford, England : 1990
17. Valachis A, Nearchou AD, Lind P (2014) Surgical management
of breast cancer in BRCA-mutation carriers: a systematic review
and meta-analysis. Breast Cancer Res Treat. doi:10.1007/s10549-
014-2890-1
18. Brandberg Y, Sandelin K, Erikson S, Jurell G, Liljegren A,
Lindblom A, Linden A, von Wachenfeldt A, Wickman M, Arver
B (2008) Psychological reactions, quality of life, and body image
after bilateral prophylactic mastectomy in women at high risk for
breast cancer: a prospective 1-year follow-up study. J Clin Oncol
26(24):3943–3949. doi:10.1200/jco.2007.13.9568
19. Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M,
Fisher ER, Jeong JH, Wolmark N (2002) Twenty-year follow-up
of a randomized trial comparing total mastectomy, lumpectomy,
and lumpectomy plus irradiation for the treatment of invasive
breast cancer. New Engl J Med 347(16):1233–1241. doi:10.1056/
NEJMoa022152
20. Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini
A, Aguilar M, Marubini E (2002) Twenty-year follow-up of a
randomized study comparing breast-conserving surgery with
radical mastectomy for early breast cancer. New Engl J Med
347(16):1227–1232. doi:10.1056/NEJMoa020989
21. Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E,
Evans DG, Izatt L, Eeles RA, Adlard J, Davidson R, Eccles D,
Cole T, Cook J, Brewer C, Tischkowitz M, Douglas F, Hodgson
S, Walker L, Porteous ME, Morrison PJ, Side LE, Kennedy MJ,
Houghton C, Donaldson A, Rogers MT, Dorkins H, Mied-
zybrodzka Z, Gregory H, Eason J, Barwell J, McCann E, Murray
A, Antoniou AC, Easton DF (2013) Cancer risks for BRCA1 and
BRCA2 mutation carriers: results from prospective analysis of
EMBRACE. J Natl Cancer Inst 105(11):812–822. doi:10.1093/
jnci/djt095
22. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E,
Godwin J, Gray R, Hicks C, James S, MacKinnon E, McGale P,
McHugh T, Peto R, Taylor C, Wang Y (2005) Effects of radio-
therapy and of differences in the extent of surgery for early breast
cancer on local recurrence and 15-year survival: an overview of
the randomised trials. Lancet 366(9503):2087–2106. doi:10.1016/
s0140-6736(05)67887-7
23. McGuire KP, Santillan AA, Kaur P, Meade T, Parbhoo J, Mathias M,
Shamehdi C, Davis M, Ramos D, Cox CE (2009) Are mastectomies
on the rise? A 13-year trend analysis of the selection of mastectomy
versus breast conservation therapy in 5865 patients. Ann Surg Oncol
16(10):2682–2690. doi:10.1245/s10434-009-0635-x
24. Heemskerk-Gerritsen BA, Menke-Pluijmers MB, Jager A, Til-
anus-Linthorst MM, Koppert LB, Obdeijn IM, van Deurzen CH,
Collee JM, Seynaeve C, Hooning MJ (2013) Substantial breast
cancer risk reduction and potential survival benefit after bilateral
mastectomy when compared with surveillance in healthy BRCA1
and BRCA2 mutation carriers: a prospective analysis. Ann Oncol
24(8):2029–2035. doi:10.1093/annonc/mdt134
25. Metcalfe K, Gershman S, Ghadirian P, Lynch HT, Snyder C,
Tung N, Kim-Sing C, Eisen A, Foulkes WD, Rosen B, Sun P,
Narod SA (2014) Contralateral mastectomy and survival after
breast cancer in carriers of BRCA1 and BRCA2 mutations: ret-
rospective analysis. BMJ (Clin Res Ed) 348:g226. doi:10.1136/
bmj.g226
578 Breast Cancer Res Treat (2014) 147:571–578
123
